6results about How to "High diagnostic efficiency" patented technology

The present application relates to the field of biotechnology, and in particular, discloses a marker for diagnosing sepsis and use thereof. The present application first discovers that serum METRNL can predict the survival of sepsis patients, and METRNL can be used as a marker for predicting the survival of sepsis patients. The AUC of METRNL combined with PCT for diagnosing sepsis can reach 1. Compared with the diagnosis effect of a single marker, the AUC value and specificity of METRNL combined with PCT are significantly improved, and sepsis patients can be completely distinguished, which is an ideal sepsis diagnostic index.

This invention discloses the application of a polypeptide as a biomarker in the diagnosis of primary osteoporosis, wherein the polypeptide has the amino acid sequence shown in SEQ ID NO.3. This invention uses a combination of two peptides for the diagnosis of primary osteoporosis, achieving high diagnostic efficacy. ROC analysis shows an AUC value of 0.945 for diagnostic significance, with a sensitivity of 92.7% and a specificity of 85.3%. Furthermore, the polypeptide with the aforementioned amino acid sequence shown in SEQ ID NO.3, obtained by linking the two peptides using a flexible GGS linker, also exhibits the same diagnostic efficacy and can be used to develop diagnostic kits for primary osteoporosis.

The present application relates to the technical field of medical detection, in particular to a biomarker combination for diagnosing gestational diabetes mellitus and application thereof. The present application provides application of SHBG protein and Vaspin protein in preparation of a product for diagnosing gestational diabetes mellitus. When SHBG and Vaspin are used in combination for diagnosing gestational diabetes mellitus, the diagnostic efficiency is extremely high, the AUC value reaches 0.934, the accuracy is 0.91, the sensitivity is 0.872, and the specificity is 0.949. The biomarker combination of the present application can be used for early diagnosis of whether there is a risk of GDM, so as to provide a basis for timely intervention, reduce the complication risk of pregnant women and fetuses, and improve the health outcomes of mothers and infants.

The invention relates to a non-invasive gastric cancer diagnosis and recurrence and metastasis evaluation biomarker based on excrement and application thereof, the biomarker is a combination of CpG loci cg14343214, cg01588438 and cg25470148 on an excrement genome and helicobacter pylori mononucleotide loci s1625711, s200977, s821562 and s1491155, and the biomarker is used for preparing a product for gastric cancer screening and / or gastric cancer prognosis evaluation. Compared with the prior art, the joint detection based on host and pathogen (Hp) double-source markers makes up for the limitation of a single detection index, and complements each other from different dimensions, so that the diagnosis efficiency is remarkably improved, the occurrence mechanism of gastric cancer can be more comprehensively revealed, and the method is suitable for popularization and application. Meanwhile, a valuable molecular basis can be provided for judging relapse and metastasis.

A kind of positioning device of intraductal lesion, the positioning device includes positioning catheter and breast ductoscope sheath cooperating with positioning catheter, breast ductoscope sheath includes mirror sheath body, hollow guide sleeve, first connector, second connector, third connector, one end of hollow guide sleeve is connected with the inside of mirror sheath body, first connector, second connector, third connector are communicated with the inside of hollow guide sleeve by mirror sheath body, positioning catheter includes intermediate pipeline and outer pipeline, outer pipeline is sleeved on the outside of intermediate pipeline, the outside of outer pipeline is equipped with the scale mark distributed along the axial direction, one end of intermediate pipeline is equipped with the liquid injection hole that can inject methylene blue.The utility model discloses by breast ductoscope sheath sends into the lesion position of breast duct with positioning catheter, and injects methylene blue, improves the accuracy of intraductal lesion position positioning and checking, reduces unnecessary resection the pain and tissue damage brought to patient.

This invention belongs to the field of biomedical technology and discloses a novel TNNT2 gene mutation c.311G>A associated with dilated cardiomyopathy. Through pedigree genetic analysis and in vitro functional validation, it was confirmed that this mutation leads to increased sensitivity of cardiomyocytes to doxorubicin and mitochondrial network fragmentation, thus exhibiting pathogenicity. Based on this, this invention provides specific detection primer pairs and kits for rapid genetic diagnosis and risk assessment of dilated cardiomyopathy.